Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 04:05PM
Prothena to Report First Quarter 2026 Financial Results on May 7 Apr 30, 2026 04:05PM
Novo Nordisk gets FDA fast track status for ATTR heart disease drug Apr 27, 2026 04:06PM
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy Apr 27, 2026 04:05PM
Prothena promotes Kingston to strategy chief, Isaacs to general counsel Apr 10, 2026 04:07PM
View Older Stories

Apr 10, 2026 04:05PM Prothena Announces Leadership Team Updates
Mar 21, 2026 04:05PM Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Mar 9, 2026 04:05PM Prothena receives $50 million milestone from Novo Nordisk for drug trial
Mar 9, 2026 04:05PM Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyop
Feb 27, 2026 04:15PM Prothena authorizes $100 million share repurchase program
Feb 27, 2026 04:15PM Prothena Announces up to $100 Million Share Repurchase Plan
Feb 19, 2026 04:05PM Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Feb 12, 2026 04:05PM Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Dec 12, 2025 04:06PM Prothena board member Paula Cobb steps down to join Manifold Bio
Dec 12, 2025 04:05PM Prothena Announces Board of Directors Update
Nov 19, 2025 04:06PM Prothena presents TDP-43 data at neuroscience conference
Nov 19, 2025 04:05PM Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
Nov 11, 2025 09:00AM Prothena highlights coramitug phase 2 data published in circulation
Nov 11, 2025 09:00AM Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
Nov 6, 2025 04:05PM Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
Oct 30, 2025 04:05PM Prothena to Report Third Quarter 2025 Financial Results on November 6
Oct 1, 2025 04:51PM BMS-986446 receives FDA fast track designation for alzheimer's treatment
Oct 1, 2025 04:45PM Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
Aug 28, 2025 04:05PM Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
Aug 27, 2025 04:05PM Prothena reports mixed results for Alzheimer's drug PRX012
Aug 27, 2025 04:05PM Prothena reports mixed results from Alzheimer's drug trial
Aug 27, 2025 04:05PM Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
Aug 6, 2025 09:00AM Novo Nordisk to advance Prothena's coramitug to phase 3 for heart disease
Aug 6, 2025 09:00AM Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
Aug 4, 2025 04:05PM Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
Jul 28, 2025 04:05PM Prothena to Report Second Quarter 2025 Financial Results on August 4
Jun 18, 2025 04:05PM Prothena Corp. (PRTA) Announces Corporate Restructuring, Revises Guidance
Jun 18, 2025 04:05PM Prothena Announces Corporate Restructuring
Jun 16, 2025 01:06AM Prothena Corp. (PRTA) Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's
Jun 16, 2025 01:06AM Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
May 23, 2025 04:14PM Prothena Corp. (PRTA) announces Phase 3 trial for Birtamimab did not meet endpoint
May 23, 2025 04:05PM Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
May 8, 2025 04:05PM Prothena Reports First Quarter 2025 Financial Results and Business Highlights
May 1, 2025 04:05PM Prothena to Report First Quarter 2025 Financial Results on May 8
Feb 20, 2025 04:05PM Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
Feb 13, 2025 04:05PM Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Dec 30, 2024 04:05PM Prothena Announces Board of Directors Update
Dec 19, 2024 01:05AM Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
Nov 12, 2024 04:05PM Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Nov 5, 2024 04:05PM Prothena to Report Third Quarter 2024 Financial Results on November 12
Sep 27, 2024 04:05PM Prothena Corp. (PRTA) Announces Leadership Team Updates
Sep 27, 2024 04:05PM Prothena Announces Leadership Team Updates
Aug 29, 2024 04:05PM Prothena to Participate in Upcoming Healthcare Conferences
Aug 8, 2024 04:05PM Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
Aug 1, 2024 04:05PM Prothena to Report Second Quarter 2024 Financial Results on August 8
May 28, 2024 04:06PM Prothena (PRTA) Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019
May 28, 2024 04:05PM Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
May 8, 2024 04:05PM Prothena Reports First Quarter 2024 Financial Results and Business Highlights
May 1, 2024 04:05PM Prothena to Report First Quarter 2024 Financial Results on May 8
Apr 15, 2024 04:06PM Prothena (PRTA) Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
View Older Stories